Prof. S. Didier

Biography

Didier, prior to joining ABIVAX, combined the functions of CEO and Scientific Directory at Splicos. Didier has a PhD in Molecular Pharmacology. He completed his post-doctoral studies at Harvard Medical School and then at the Stanford University School of Medicine. Research Director at Entelos (California – USA) from 2000 to 2005, he then joined the Research Department of Astra-Zeneca as Associate Director (Capability Pathways – Discovery Enabling Capabilities and Sciences), and then as Head of Research, at LFB Biotechnologies where he led a team of fifty scientists in charge of developing the portfolio of therapeutic proteins in oncology, autoimmune diseases and hematology-oncology. He is the author of numerous publications and presentations in the field of systems biology applied to the research and drug development. Didier, prior to joining ABIVAX, combined the functions of CEO and Scientific Directory at Splicos. Didier has a PhD in Molecular Pharmacology. He completed his post-doctoral studies at Harvard Medical School and then at the Stanford University School of Medicine. Research Director at Entelos (California – USA) from 2000 to 2005, he then joined the Research Department of Astra-Zeneca as Associate Director (Capability Pathways – Discovery Enabling Capabilities and Sciences), and then as Head of Research, at LFB Biotechnologies where he led a team of fifty scientists in charge of developing the portfolio of therapeutic proteins in oncology, autoimmune diseases and hematology-oncology. He is the author of numerous publications and presentations in the field of systems biology applied to the research and drug development.

Research Interest

therapeutic proteins in oncology, autoimmune diseases and hematology-oncology.